The organisation for the 22nd joint meeting held by kConFab, ISK, ABCFS, ACCFS, Lifepool and the Family Cancer Clinics of Australia for August - September 2022 is progressing well and we will hold a face-to-face and on-line meeting.

Although the named consortia are funded in very different ways and have no official connections, all groups share a common interest in familial and population based cancer. For example, kConFab recruits families at high genetic risk of breast, ovarian and prostate cancer through Family Cancer Clinics located in every State and Territory of Australia and return our research generated germ-line mutation test results back to family members and the relevant treating FCC. In one sense kConFab is the research arm of the national Family Cancer Clinics. Many of the consortia members are health professionals (medical oncologists, surgeons, genetic counsellors, cancer specialists, research scientists) working in the Family Cancer Clinics and major research institutions through-out Australia and New Zealand.

A joint annual meeting has particular value for the groups mentioned as it provides a forum to develop and discuss new research findings, clinical trials and implementation of technologies about families with multiple cases of breast, ovarian, prostate, endometrial melanoma, sarcoma, leukaemia and colorectal cancers.

 

FAC 2022 will be delivered in a hybrid format, combining an in-person conference experience with an online component.

In-Person attendees will experience all the usual highlights of the FAC meeting, including leading keynote presentations, opportunity to submit abstracts to present an oral or poster presentation, opportunity to attend breakout sessions, networking opportunities and an industry exhibition.

Virtual attendees will be able to view the live-streamed presentations in the plenary sessions and participate in the Q & A. They also have the opportunity to submit abstracts and present an oral or poster presentation.

We are aiming for a hybrid event - in-person with a virtual component however our back up plan in the event the conference is impacted by COVID-19 will be a fully virtual conference.  Please read our Refund Policy to find out what happens in the event of COVID-19 impacting the conference HERE.  

• Colorectal cancer and polyposis

• Endocrine cancer

• Rare gynaecological cancers

• Incorporating tumour testing into germline results

• Genetics of breast, ovarian, prostate, colorectal cancer susceptibility genes and sarcoma

• Haematological malignancy genomics

• Polygenic Risk Score and cancer risk

• Tumour-meets-Germline

• The value of surveillance in changing clinical practice

• Secondary findings from genomic analysis

• Antonis Antoniou, Professor of Cancer Risk Prediction, University of Cambridge, UK

• Joep Bogaerts, Pathologist (Gynecology) RadboudUMC Nijmegen, The Netherlands

• Lucy Godley, Hospira Foundation Professor of Medicine and Human Genetics, University of Chicago Medicine, USA

• Paul Goodfellow, Professor Obstetrics and Gynecology, James CCC Ohio State University , USA

• Joanne Kotsopoulos, Associate Professor, Canada Research Chair in Hereditary Breast and Ovarian Cancer Prevention, Women’s College Hospital, University of Toronto, Canada

• Megan Roberts, Assistant Professor, Director, Implementation Science in Precision Health & Society, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, USA

• William Stevenson, Royal North Shore, NSW

Mandy Ballanger, Garvan Institute of Medical Research, Sydney

Lisa Devereux, The Peter MacCallum Cancer Centre, Melbourne

Laura Forrest, The Peter MacCallum Cancer Centre, Melbourne

Shuai Li, The University of Melbourne, Melbourne

Finlay Macrae, The Royal Melbourne Hospital, Melbourne

Christobel Saunders, The Royal Melbourne Hospital, Melbourne

Rodney Scott, NSW Health Pathology Hunter, Newcastle

Melissa Southey, Monash University, Melbourne

Lucinda Salmon, The Austin Hospital, Melbourne

Heather Thorne, The Peter MacCallum Cancer Centre, Melbourne

Rachel Williams, Prince of Wales Hospital, Sydney

Milita Zaheed, Prince of Wales Hospital, Sydney